HLX-22 is a humanized monoclonal antibody targeting HER2. When used in combination with trastuzumab, HLX-22 can induce apoptosis in HER2-overexpressing breast and gastric cancer cells. It also exhibits potent antitumor activity against advanced solid tumors.
CAS Nummer:
[2851060-90-5]
Target-Kategorie:
EGFR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten